Veterinary Vaccine Production Centre, Gannoruwa, Peradeniya, Sri Lanka.
Vaccine. 2010 Mar 8;28(11):2284-9. doi: 10.1016/j.vaccine.2009.12.068. Epub 2010 Jan 20.
Fowl cholera is a serious problem in large and small scale poultry production. The present study describes the development and testing of an inactivated whole-cell, low-cost, safe, and effective vaccine for fowl cholera based on a previous work (Vaccine 23:5590-5598). Pasteurella multocida A: 1 grown in the presence of low FeCl(3) concentrations, inactivated with higher concentrations of FeCl(3), and adjuvanted with bacterial DNA from P. multocida B: 2 containing immunostimulatory CpG motifs protect chickens with a lethal P. multocida A: 1 challenge. Chickens were immunized with two whole-cell inactivated vaccine doses at 4 weeks apart and challenged 4 weeks after booster immunization. Experimental vaccines were pure, easy injectable, and caused very little distress in chickens due to their aqueous consistency. Vaccines and bacterial DNA (bDNA) posed no safety problems when chickens were injected subcutaneously (s.c.) with a single, double, and overdose of these preparations. Immunized chickens produced systemic IgY antibodies (Ab) responses and vaccine adjuvanted with bDNA protected 100% chickens from lethal intrapertoneal (i.p.) P. multocida A: 1 challenge. This work suggests that use of bDNA as an adjuvant can improve the cost-effectiveness of inactivated veterinary vaccines for their use in developing countries. Our future studies will focus on safety and potency evaluation of experimental and current vaccines using bDNA as an adjuvant.
禽霍乱是大、小规模家禽生产中的一个严重问题。本研究描述了一种基于先前工作(Vaccine 23:5590-5598)的新型、低成本、安全且有效的禽霍乱灭活全细胞疫苗的开发和测试。在低浓度 FeCl3 存在下生长的多杀性巴氏杆菌 A:1,用较高浓度的 FeCl3 灭活,并与含有免疫刺激性 CpG 基序的多杀性巴氏杆菌 B:2 细菌 DNA 佐剂混合,可保护鸡免受致死性多杀性巴氏杆菌 A:1 攻击。鸡用两剂全细胞灭活疫苗免疫,间隔 4 周,加强免疫后 4 周进行攻毒。实验疫苗纯净,易于注射,由于其水相一致性,对鸡造成的不适很少。当鸡通过皮下(s.c.)注射单一、双剂量和超剂量这些制剂时,疫苗和细菌 DNA(bDNA)不会造成安全问题。免疫鸡产生全身性 IgY 抗体(Ab)反应,并用 bDNA 佐剂的疫苗可保护 100%的鸡免受致死性腹腔内(i.p.)多杀性巴氏杆菌 A:1 攻击。这项工作表明,使用 bDNA 作为佐剂可以提高灭活兽医疫苗的成本效益,使其在发展中国家得到应用。我们未来的研究将集中在使用 bDNA 作为佐剂的实验和现有疫苗的安全性和效力评估上。